Top 10 drugs
Top 10 drugs
- Aust Prescr 2012;35:69
- 3 December 2012
- DOI: 10.18773/austprescr.2012.091
These tables show the top 10 subsidised drugs for the year July 2011 – June 2012.
Table 1 Top 10 drugs by DDD/1000 pop/day *†
DDDs in this table include use in combination products |
Table 2 Top 10 drugs by prescription counts †
|
| Drug | Cost to government (A$) |
DDD/1000 pop/day* PBS/RPBS ‡ |
Prescriptions PBS/RPBS ‡ |
| 1. atorvastatin | 606 051 755 | 82.99 | 10 855 535 |
| 2. rosuvastatin | 369 088 997 | 38.14 | 7 035 996 |
| 3. ranibizumab | 367 753 306 | § | 172 785 |
| 4. adalimumab | 205 117 624 | 0.39 | 115 277 |
| 5. esomeprazole | 178 922 823 | 21.91 | 6 069 831 |
| 6. salmeterol and fluticasone | 177 315 166 | ¶ | 3 130 577 |
| 7. olanzapine | 159 400 059 | 3.05 | 965 797 |
| 8. clopidogrel | 139 521 901 | 11.00 | 2 635 142 |
| 9. etanercept | 131 116 800 | 0.26 | 74 605 |
| 10. rituximab | 129 299 223 | § | 59 284 |
* The defined daily dose (DDD)/thousand population/day is a more useful measure of drug utilisation than prescription counts. It shows how many people in every thousand Australians are taking the standard dose of a drug every day. (For WHO definition of DDD see www.whocc.no/ddd/definition_and_general_considera/)
† Based on date of supply. Does not include private prescriptions or prescriptions under PBS co-payment.
‡ PBS Pharmaceutical Benefits Scheme, RPBS Repatriation Pharmaceutical Benefits Scheme
§ The World Health Organization has not allocated a DDD for this drug
¶ This combination does not have a DDD allocated Source: Drug Utilisation Sub-Committee (DUSC) Database, as at 3 October 2012. © Commonwealth of Australia.
Data are based on date of supply with processing date up to the month of September 2012. Data exclude 'Under co-payment' and 'Closing the gap' prescriptions processed by the Department of Human Services.